Pipeline

Cell Medica is committed to transforming the lives of patients with cancer by developing the therapeutic potential of off-the-shelf engineered T cell therapies.

Our current focus endeavors to harness the natural biology of a specific subset of cytotoxic T cells, called Natural Killer T cells (NKT cells).

NKT cells demonstrate several important biological differences when compared to conventional T cells, which we believe render them  particularly well suited to the development of off-the-shelf chimeric antigen receptor therapies (CAR) for the treatment of patients with both solid and hematological tumors. In addition to the introduction of a CAR, we have also engineered aspects of the resulting CAR-NKT cells to further optimize their function, potency and therapeutic effect.

Our innovative CAR-NKT candidates are being developed in collaboration with Baylor College of Medicine and University of North Carolina. The first CAR-NKT product is currently in Phase I clinical trials.

The company’s ambition is to develop a growing portfolio of CAR-NKT products to treat broad populations of patients in need, across multiple highly prevalent tumor types.

Cell Medica is also exploring other innovative preclinical programs in the field of engineered T cell therapy, based on the innovative Dominant TCR platform technology developed at University College London, which we hope to progress further over time.

CAR-NKT

We are developing a range of innovative Chimeric Antigen Receptor (CAR) NKT cell products that allow for multiple target-specific constructs in both the allogeneic and autologous settings. NKT cells contain an invariant T cell receptor which confers distinct advantages over T-cells in the allogeneic (off-the-shelf) setting. Our novel constructs incorporate IL-15 to improve persistence and expansion.

Other technologies

Cell Medica has a robust pipeline of cellular immunotherapy products.

In the field of engineered TCRs, we are working with University College London, to develop the Dominant TCR technology to improve the potency of TCR-modified T cells while maintaining the safety profile.

Our product portfolio also includes baltaleucel-T (CMD-003, EBV-specific T cells) for the treatment of lymphomas associated with the Epstein Barr virus.